Loading stock data…
OrthoPediatrics Corp. (KIDS)
$22.22-0.19 (-0.85%)
Market ClosedLast close Sep 8
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OrthoPediatrics Corp. in the Healthcare sector is trading at $22.22 with a market capitalization of $648M. Wall Street consensus targets $27.22 (9 analysts), implying a +22.5% move over the next 12 months. The stock is currently 17% below its 52-week high of $26.74, remaining 19.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +22.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 22) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $70.51M↑ | $59.36M↓ | $61.60M↑ | $61.25M↑ | $61.08M |
| Gross Profit | $52.37M↑ | $43.39M↓ | $45.11M↓ | $45.27M↑ | $44.02M |
| Operating Income | -$4.07M↑ | -$8.34M↓ | -$5.51M↓ | -$4.87M↑ | -$7.69M |
| Net Income | -$7.16M↑ | -$10.69M↓ | -$10.10M↑ | -$11.77M↓ | -$7.11M |
Peer Comparison
JNJUNHPFE
Fundamentals
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$647.52M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.96
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.56%
Volume
Today's trading volume
119,292
Recent News
OrthoPediatrics Sees ‘Inflection Point’ as New Products Fuel Record Quarter
OrthoPediatrics (NASDAQ:KIDS) reported record revenue, adjusted EBITDA and number of children helped during the second quarter, as the pediatric orthopedic device company began to see early contributions from its newer “super cycle” products, Chief Executive Officer Dave Bailey said at the Canaccord
OrthoPediatrics (KIDS) Q2 2026 Earnings Call Transcript
Trauma and deformity revenue surged 26% as adjusted EBITDA hit record $6.8 million.
OrthoPediatrics Corp. Q2 2026 Earnings Call Summary
Moby summary of OrthoPediatrics Corp.'s Q2 2026 earnings call
OrthoPediatrics Corp (KIDS) (Q2 2026) Earnings Call Highlights: Record Revenue and EBITDA ...
OrthoPediatrics Corp (KIDS) posts 15% revenue growth and raises full-year guidance amid strong trauma and deformity performance.
OrthoPediatrics Q2 Earnings Call Highlights
OrthoPediatrics (NASDAQ:KIDS) reported record second-quarter revenue of $70.5 million, up 15% from a year earlier, as strong Trauma & Deformity and specialty bracing performance offset a reported decline in scoliosis revenue. The company also raised its 2026 revenue outlook while maintaining its